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N- Linked Glycans in the Variable Domain of IgG  
Anti–Citrullinated Protein Antibodies Predict the 
Development of Rheumatoid Arthritis
Lise Hafkenscheid,1  Emma de Moel,1 Irene Smolik,2 Stacey Tanner,2  Xiaobo Meng,2 Bas C. Jansen,3 
Albert Bondt,1  Manfred Wuhrer,1 Tom W. J. Huizinga,1 Rene E. M. Toes,1 Hani El-Gabalawy,2 and  
Hans U. Scherer1
Objective. Anti–citrullinated protein antibodies (ACPAs) are disease- specific biomarkers in rheumatoid arthritis 
(RA). More than 90% of IgG ACPAs harbor N- linked glycans in the antibody variable (V) domain. The corresponding 
N- glycosylation sites in ACPA V- region sequences result from somatic hypermutation, a T cell–dependent process. 
As ample evidence indicates that T cells drive the maturation of the ACPA response prior to arthritis onset, we under-
took this study to investigate whether the presence of glycans in IgG ACPA V domains predicts the transition from 
predisease autoimmunity to overt RA.
Methods. We analyzed 2 independent sets of serum samples obtained from 126 ACPA- positive first- degree 
relatives (FDRs) of RA patients. Both sets originated from an Indigenous North American population and comprised 
cross- sectional and longitudinal samples of individuals who did or did not develop inflammatory arthritis. Serum IgG 
ACPAs were affinity- purified and subjected to ultra high- performance liquid chromatography–based glycan analysis.
Results. In both data sets, FDR- derived IgG ACPA displayed markedly lower levels of V domain glycans (<50%) 
compared to IgG ACPA from RA patients. Notably, FDRs who later developed RA showed extensive V- domain glyco-
sylation before the onset of arthritis. Moreover, IgG ACPA V- domain glycosylation was strongly associated with future 
development of RA (hazard ratio 6.07 [95% confidence interval 1.46–25.2]; P = 0.013).
Conclusion. Extensive glycosylation of the IgG ACPA V domain is present in a subset of predisposed FDRs of 
Indigenous North American RA patients. The presence of this feature substantially increases the risk of RA devel-
opment. Based on these findings, we propose that glycosylation of the IgG ACPA V domain represents a predictive 
marker for RA development in ACPA- positive individuals and may serve to better target prevention measures.
INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease. Approximately 1% of the global population is affected, but 
higher prevalence rates have been observed in certain defined 
populations, such as Indigenous North Americans (1,2). Indige-
nous North Americans develop RA at a younger age, experience 
higher disease burden, have a remarkably high prevalence of the 
major genetic risk factor for RA (HLA class II shared epitope [SE] 
alleles) (3), and develop RA that is primarily seropositive for RA- 
associated autoantibodies, particularly anti–citrullinated protein 
antibodies (ACPAs) (4).
It is now well established that ACPAs can be present for 
many years without evidence of clinical symptoms of RA (5). 
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Notably, ACPA levels, isotype usage, and the citrullinated antigen 
recognition profile broaden relatively close to the onset of arthritis 
(6). Thus, it has been postulated that the development of ACPA- 
positive disease is a multistep process (7–9), in which tolerance to 
citrullinated antigens is initially broken, followed by a putative “sec-
ond hit” that leads to the expansion of the ACPA response and, 
ultimately, to development of clinically detectable disease. Hence, 
it has become of considerable interest to understand the drivers 
of this predisease expansion of the ACPA response and to identify 
markers that predict the transition from asymptomatic autoimmu-
nity to ACPA- positive inflammatory arthritis (IA). Interestingly, recent 
immunogenetic evidence indicates that HLA SE alleles might con-
tribute to the expansion of the ACPA response by facilitating the 
provision of T helper cell activity to ACPA- expressing B cells. This 
is based on the observation that HLA SE alleles are risk factors 
for ACPA- positive disease but do not predispose to the devel-
opment of ACPA positivity in healthy individuals (10,11). Thus, it 
can be hypothesized that in individuals destined to develop RA, 
ACPA- expressing B cells receive predisease T cell “help” that initi-
ates and drives B cell maturation, including isotype switching and 
somatic hypermutation (SHM) (6).
Recently, we found that almost all IgG ACPA molecules 
carry N- glycans in their B cell receptor variable (V) domains 
(12,13). Notably, all of the consensus N- glycosylation sequences 
(Asn- X [≠Pro]–Ser/Thr) found in these V regions were generated 
upon SHM and not encoded in the germline genetic repertoire 
(14). Moreover, we found evidence that the generation of such 
N- glycosylation sites offers an advantage to ACPA- expressing B 
cells that helps with their escape from selection checkpoints, as 
these cells acquire extensive somatic mutations despite a lack of 
avidity maturation. Together, these observations are consistent 
with the notion that T cells have a pivotal role in the selection and 
expansion of ACPA- expressing B cells, possibly by facilitating the 
introduction of N- glycosylation sites in IgG ACPA V domains.
Based on these considerations, we hypothesized that 
the detection of IgG ACPA V- domain glycosylation in ACPA- 
positive individuals is indicative of maturation of this autoim-
mune response and could potentially serve as a predictor for the 
development of ACPA- positive RA. To address this hypothesis, 
we analyzed IgG ACPA V- domain glycosylation in a longitudinal 
manner in unaffected ACPA- positive first- degree relatives (FDRs) 
of RA patients in an Indigenous North American population pre-
disposed to the disease. We determined that there is a hetero-
geneity of IgG ACPA V- domain glycosylation levels in unaffected 
FDRs and that high levels, comparable to those seen in most 
RA patients, serve to substantially increase the risk of future RA 
development.
PATIENTS AND METHODS
Study population. The current study is nested within a 
longitudinal research project initiated in 2005 entitled “Early Iden-
tification of Rheumatoid Arthritis in First Nations,” that was based 
at the Arthritis Centre at the University of Manitoba. The study and 
its consenting process were fully approved by the University of 
Manitoba Research Ethics Board and the Band Councils of the 
study’s participating communities, the latter based on specific 
study agreements with the communities (15). Sera were sent in 
2 sets, in a blinded manner, to Leiden University Medical Center. 
The first set was collected from a cross- sectional cohort consist-
ing of 10 RA patients and 84 ACPA- positive FDRs. A second set 
of samples represented a longitudinal cohort of FDRs who had 
serial visits. As a quality control measure, there was intentional 
overlap, with 11 FDRs being in both sets (Table 1 and Supple-
mentary Figure 1, on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.40920/ abstract). 
Additional information on study design and IA case definition are 
available in the Supplementary Methods.
Table 1. Patient characteristics*
Age, 
mean ± 
SD years
Female 
sex, no. 
(%)
CCP- 3, 
mean ± 
SD titer
Follow- up 
duration, 
mean ± SD 
months
Cross- sectional cohort
 RA patients (n = 10)† 50 ± 10 9 (90) 148 ± 71 –
 FDRs (n = 84) 38 ± 14 55 (65) 66 ± 68 –
 FDRs included based on IgG ACPA QC (n = 15) 36 ± 12 11 (73) 131 ± 124 –
Longitudinal cohort
 Transitioned FDRs (n = 13)‡ 34 ± 14 9 (69) 122 ± 120 50 ± 28
 Nontransitioned FDRs (n = 19)§ 39 ± 15 12 (63) 49 ± 85 64 ± 24
 Nontransitioned FDRs included based on IgG ACPA QC (n = 15) 40 ± 18 11 (73) 62 ± 90 45 ± 29
* For relationships between donors, quality control, and number of samples, see Supplementary Figure 1 and Supplemen-
tary Methods (http://onlin elibr ary.wiley.com/doi/10.1002/art.40920/ abstract). CCP- 3 = cyclic citrullinated peptide 3. 
† Median disease duration of rheumatoid arthritis (RA) patients was 6.8 years (interquartile range 2.9–18.7). After quality 
control (QC) measures, samples from all 10 RA patients were included for analysis of IgG anti–citrullinated protein anti-
bodies (ACPAs). 
‡ After QC measures, samples from all 13 transitioned first- degree relatives (FDRs) were included for analysis of IgG and 
analysis of IgG ACPA. The mean ± SD follow- up duration for samples included for analysis of IgG ACPA was 46 ± 24 months. 
§ After QC measures, samples from all 19 nontransitioned FDRs were included for analysis of IgG. 
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Isolation of IgG ACPA and of total IgG depleted 
of ACPA. IgG ACPA and IgG were captured as previously 
described (16). Briefly, ACPA were purified from 25 μl serum by 
antigen affinity chromatography using NeutrAvidin Plus Ultra-
Link beads (Thermo Scientific) coated with cyclic citrullinated 
peptide 2 (CCP- 2). Incubation was performed by shaking the 
plate for 2 hours at room temperature. The flowthrough was 
collected by centrifugation. Beads were washed with phos-
phate buffered saline, and ACPAs were eluted with formic 
acid and immediately neutralized (16). IgG and IgG ACPAs 
were subsequently isolated in a similar manner using 20 μl 
Protein G Sepharose (GE Healthcare Life Sciences). Two hun-
dred microliters of ACPA elution or 15 μl of the flowthrough 
was loaded onto protein G beads and incubated by shaking 
at room temperature. Elution was performed with formic acid 
and centrifugation at 50g for 1 minute.
Glycan analysis. Glycans were isolated and analyzed as 
previously described (12). Briefly, IgG and IgG ACPA eluates 
were dried by vacuum centrifugation. Glycans were released 
using PNGase F (Roche) and labeled with 2- aminobenzoic 
acid (2- AA) and 2- picoline borane (Sigma- Aldrich). The 2- 
AA–labeled glycans were purified via hydrophilic interaction 
liquid chromatography–solid phase extraction (HILIC- SPE) 
using multiwell filter plates, as previously described (17,18). 
HILIC- SPE–purified 2- AA–labeled glycans were diluted 
in 100% acetonitrile and injected into a UHPLC Dionex 
Ultimate 3000 (ThermoFisher Scientific) equipped with an 
Acquity UHPLC BEH Glycan column and a fluorescence 
detector.
Data analysis. HappyTools was used to align, calibrate, 
and integrate the raw emissions of the chromatograms exported 
from Chromeleon, version 7.1.2.1713 (ThermoFisher Scientific) 
(19). The calibrations list, settings, and quality control mea-
surements are provided in the Supplementary Methods and 
Supplementary Tables 1 and 2 (http://onlin elibr ary.wiley.com/
doi/10.1002/art.40920/ abstract). V- domain glycosylation was 
calculated using the following formula: percentage V- domain 
glycosylation = (V- domain glycans/Fc glycans) × 100, where the 
V- domain glycans were GP19 plus GP23 plus GP24, and the Fc 
glycans were GP4 plus GP8 plus GP14. We selected the gly-
cans used for the calculation based on our previous observation 
of their respective, exclusive presence in either the Fc portion 
or in the V domain (12,13) (Supplementary Figure 2). IgG ACPA 
glycan profiles could be obtained for all 10 RA samples from 
the cross- sectional cohort; 15 of the 84 FDR samples showed 
IgG ACPA glycan profiles that met the criteria. In the longitudi-
nal cohort, 67 of the 117 samples from the FDRs yielded suffi-
cient signal to determine the IgG ACPA glycan profile (Table 1 
and Supplementary Figure 1, http://onlin elibr ary.wiley.com/
doi/10.1002/art.40920/ abstract).
Statistical analysis. In the cross- sectional cohort, the 
percentage of V- domain glycosylation between RA patients and 
FDRs was compared by Mann- Whitney U test. In the longitudinal 
cohort, levels of V- domain glycosylation over time were com-
pared between FDRs who developed RA and those who did not, 
using linear mixed models with a random intercept and slope. A 
multivariable Cox proportional hazards regression analysis was 
performed, with RA diagnosis as outcome and V- domain glyco-
sylation level as predictor. We used V- domain glycosylation at 
the first moment of sampling, dichotomized as above or below 
the group median to draw Kaplan- Meier survival curves and 
estimate risk of developing RA. Receiver operating characteristic 
curve (ROC) regression was used to calculate diagnostic prop-
erties. All analyses in the longitudinal cohort included adjustment 
for age and sex and were conducted using Stata SE 14.1. All 
reported percentage values refer to IgG ACPA V- domain glyco-
sylation levels and not to relative changes. Hazard ratios (HRs) 
and 95% confidence intervals (95% CIs) were calculated.
RESULTS
Lower levels of ACPA V- domain glycosylation in 
ACPA- positive healthy FDRs compared to RA patients. 
Previously, we demonstrated that IgG ACPAs, in contrast to other 
antigen- specific IgG molecules (e.g., IgG against tetanus toxoid), 
are hyperglycosylated in the V domain in patients with established 
RA. These glycans are biantennary N- linked glycans that are fully 
galactosylated and sialylated (12,13). Although ACPA can be pres-
ent before disease onset in individuals who will eventually develop 
RA, the V- domain glycosylation state of ACPA has not been studied 
in the predisease phase. To address this question, IgG ACPAs were 
isolated from the serum of ACPA- positive Indigenous North Ameri-
can patients with RA and their unaffected ACPA- positive FDRs. By 
analyzing an initial cross- sectional set of samples, we observed that 
FDR- derived IgG ACPA showed, on average, substantially lower 
levels of V- domain glycosylation than IgG ACPA from patients with 
established RA (Supplementary Figure 3A, http://onlin elibr ary.wiley.
com/doi/10.1002/art.40920/ abstract). Notably, the levels of V- do-
main glycosylation of IgG ACPA isolated from Indigenous North 
American RA patients were comparable to the levels we previously 
reported in Dutch RA patients (112% versus 93%, respectively) 
(12). Additionally, tetanus toxoid–specific IgG in Indigenous North 
American RA patients did not show the enhanced V- domain N- 
glycosylation observed in IgG ACPA, which is consistent with our 
previous observations in Dutch RA patients (data not shown) (13,14).
Analysis of a second set of samples derived from longitu-
dinally followed up, unaffected, ACPA- positive FDRs essentially 
replicated the cross- sectional results, which demonstrated low 
levels of IgG ACPA V- domain glycosylation compared to those 
in RA patients (Supplementary Figure 3B, http://onlin elibr ary.wiley.
com/doi/10.1002/art.40920/ abstract). For subsequent group- 
level analyses, we combined the IgG ACPA V- domain glycosyl-
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ation data from the initial cross- sectional cohort with the data 
from baseline samples from the FDRs included in the longitudinal 
cohort (Figure  1A). Thus, each individual FDR contributed only 
once to the analysis, but overall this approach served to increase 
sample size and statistical power of the analysis.
FDRs displayed heterogeneous levels of IgG ACPA V- domain 
glycosylation. This observation prompted us to analyze whether 
FDRs with high levels subsequently developed clinically detectable 
IA. As depicted in Figure 1B (and in Supplementary Figures 3A and 
B, http://onlin elibr ary.wiley.com/doi/10.1002/art.40920/ abstract), 
FDRs who transitioned to a state of clinically detectable IA later in 
life had substantially higher levels of IgG ACPA V- domain glycosyla-
tion compared to individuals who did not transition during follow- up 
(89% versus 20%; P < 0.0001). Furthermore, a small portion of 
FDRs reported new arthralgia; these individuals demonstrated higher 
IgG ACPA V- domain glycosylation levels compared to FDRs who 
remained asymptomatic (Supplementary Figure 3). Therefore, the ini-
tially unaffected FDRs who subsequently developed clinically detect-
able IA or new- onset arthralgia displayed high levels compared to 
FDRs who remained in an unaffected or asymptomatic state.
Association of high IgG ACPA V- domain glycosyl-
ation levels in FDRs and development of RA. The obser-
vation that unaffected FDRs who developed IA later in life had 
significantly higher IgG ACPA V- domain glycosylation levels than 
FDRs who did not develop IA (Figure 1B) prompted us to deter-
mine the time course of glycosylation in these individuals. Intrigu-
ingly, we observed that V- domain glycosylation levels were already 
increased in some FDRs up to 7 years before the onset of arthritis. 
Other individuals who developed IA showed an increase in gly-
cosylation ~1–2 years before disease onset (Figure 2A). When all 
available time points were considered, IgG ACPA V- domain gly-
cosylation was 34% higher (95% CI 7–62%) in FDRs who devel-
oped IA compared to FDRs who did not (P = 0.015) (Figure 2B). 
Notably, FDRs with new- onset arthralgia were classified as non-
transitioned. Taken together, these data indicate that ACPA- 
positive individuals who subsequently developed IA displayed a 
high degree of IgG ACPA V- domain glycosylation in the preclinical 
phase. The time course for development of IA, however, varied 
considerably between individuals.
Absence of elevated V- domain glycosylation in IgG 
ACPA. The degree of V- domain glycosylation of IgG ACPA is 
remarkably high compared to other IgG molecules. To date, we 
have been unable to identify another autoreactive B cell response 
with comparably high levels of V- domain glycans (12,13). Further-
more, among the Dutch RA population, non- ACPA IgG V- domain 
glycosylation levels were only 17%. To confirm that non- ACPA 
IgG V- domain glycosylation is also low in the Indigenous North 
American population and to investigate a potential association 
with clinical outcome, we used the flowthrough of the ACPA iso-
lation columns to further purify non- ACPA IgG from FDR- derived 
sera, followed by glycosylation analysis as it was performed for 
IgG ACPA. V- domain glycosylation of non- ACPA IgG was as low 
as 15–25% in these samples, with a mean of 17% for FDRs who 
did not develop IA and 20% for those who did (P not significant) 
(Figure 3). These levels are consistent with published data on IgG 
in healthy individuals (12,20). Moreover, the degree of V- domain 
glycosylation remained low over time and showed no differences 
in mean levels between transitioning and nontransitioning FDRs (P 
= 0.33). These data suggest that increased V- domain glycosyla-
tion is not a feature of non- ACPA IgG and that this phenomenon is 
inherent in the citrulline- directed immune response.
Elevated IgG ACPA V- domain glycosylation level as 
a predictive marker for disease development in ACPA- 
positive at- risk subjects. Given that FDRs who developed 
IA had higher levels of IgG ACPA V- domain glycosylation over 
time compared to those who did not, we attempted to cre-
ate models of glycosylation as a predictor of IA development. 
To account for the variance between time points and duration 
of follow- up of available study subjects, 2 statistical models 
were established. In the first model, we used the median IgG 
ACPA V- domain glycosylation level in the cross- sectional anal-
ysis (58%) as a cutoff point, thus generating a binary variable. 
Cox regression analysis, corrected for age and sex, revealed 
that IgG ACPA V- domain glycosylation levels above the median 
were associated with development of IA (HR 6.07 [95% CI 
1.46–25.2]; P = 0.013) (Figure  4). A similar cutoff point was 
Figure 1. Anti–citrullinated protein antibody (ACPA)–positive first- 
degree relatives (FDRs) have lower levels of IgG ACPA variable 
(V)– domain glycosylation than do patients with clinically evident 
rheumatoid arthritis (RA). Percentages of IgG ACPA V- domain 
glycosylation in RA patients versus unaffected FDRs (A) and in FDRs 
who transitioned to inflammatory arthritis versus those who did not 
(B) are shown. Symbols represent individual subjects; bars show 
the median. *** = P < 0.001; **** = P < 0.0001. Color figure can be 
viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.40920/abstract.
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created when ROC regression was used to determine the pre-
dictive value of high IgG ACPA V- domain glycosylation levels. 
At this cutoff point, IgG ACPA V- domain glycosylation had 
a sensitivity of 76.9% (95% CI 46.2–95.0%), a specificity of 
78.6% (95% CI 49.2–95.3%), a positive predictive value (PPV) 
of 76.9% (95% CI 46.2–95.0%), and a negative predictive value 
(NPV) of 78.6% (95% CI 49.2–95.3%) for IA development.
DISCUSSION
IgG ACPA represents the most relevant prognostic and 
diagnostic biomarker in RA and is associated with poor prog-
nosis and progressive joint destruction (21). A large body 
of evidence indicates that early intervention in RA improves 
clinical outcomes (22,23). Based on these observations, it is 
hypothesized that intervention at a stage prior to the onset 
of clinically detectable arthritis may result in better clinical 
outcomes and possibly even prevent disease (22). Currently, 
this preclinical phase is identified based on the presence of 
suggestive joint symptoms such as arthralgia, the detection 
of RA- associated autoantibodies, especially ACPA, or both of 
these factors. Imaging studies indicate that this clinical phe-
notype may also feature subclinical synovitis (22,24). Although 
arthralgia in conjunction with a broad autoantibody response is 
a strong predictor of imminent RA onset, a linear progression 
toward these features has been difficult to demonstrate (25). 
In particular, the existing longitudinal data suggest that a con-
siderable proportion of individuals with ACPA do not develop 
RA. Thus, it has become increasingly important to delineate 
biomarkers that can be used to improve the risk model and 
that in turn provide actionable clinical information on which 
interventions can be based (24,26). Our current study demon-
strates that the glycosylation state of the IgG ACPA V domain 
may serve such a purpose. We found that the presence of 
Figure 2. IgG ACPA V- domain glycosylation is elevated in FDRs who transitioned to RA during follow- up. A, Longitudinal data on IgG ACPA 
V- domain glycosylation. Time of RA diagnosis is shown with a red cross; lines without crosses indicate that the patient transitioned to RA but 
did not have a sample obtained at the time of diagnosis. B, Median IgG ACPA V- domain glycosylation levels in FDRs who transitioned to RA 
versus those who did not. Bars show the median and range. Dotted lines indicate the range of IgG V- domain glycosylation observed in healthy 
individuals. See Figure 1 for definitions.
Figure  3. IgG depleted of ACPA does not display enhanced levels of V- domain glycosylation. A, Longitudinal data on IgG V- domain 
glycosylation. Time of RA diagnosis is shown with a red cross; lines without crosses indicate that the patient transitioned to RA but did not 
have a sample obtained at the time of diagnosis. B, Median IgG V- domain glycosylation levels in FDRs who transitioned to RA versus those 
who did not. Bars show the median and range. Dotted lines indicate the range of IgG V- domain glycosylation observed in healthy individuals. 
See Figure 1 for definitions.
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extensive IgG ACPA V- domain glycosylation in unaffected 
ACPA- positive individuals is a strong predictor of progression 
toward disease. Indeed, a high level of IgG ACPA V- domain 
glycosylation had a PPV of 76.9% and an NPV of 78.6% for 
predicting the development of IA.
Considering these clinical implications, the present data refine 
our understanding of the ACPA immune response and its predis-
ease evolution. Conceptually, the development of ACPA- positive RA 
has been proposed as a multistep process (7,8) in which the break 
in immune tolerance to citrullinated antigens develops first, fol-
lowed by expansion and maturation of the autoimmune response, 
a so- called second hit. Recent evidence suggests that this putative 
second hit is driven by T helper cells that provide help to ACPA- 
expressing B cells. This T cell–B cell interaction, which likely mediates 
the increased usage of isotypes and epitope spreading observed 
before disease onset, may also be responsible for the introduction 
of N- glycosylation sites in the V domain of IgG ACPA and, there-
fore, the presence of glycans in this region. This hypothesis is further 
supported by the observation that the consensus sequences for 
N- glycosylation sites in IgG ACPA V domains are not encoded in 
their respective germline genes but introduced upon SHM (14). In 
fact, the presence, frequency, and distribution of these sites suggest 
a role of the glycans in the selection, development, and activation of 
the B and plasma cells that express/secrete IgG ACPA.
Notably, the ACPA- positive FDRs examined here exhibited 
lower levels of IgG ACPA V- domain glycosylation than their rel-
atives with RA, but there was considerable heterogeneity in the 
population. As a matter of fact, a subset of FDRs had high levels 
of V- domain glycosylation, which in some cases was detectable 
years before disease onset. Individuals who exhibited fluctuation 
between low and normal levels over time (15–25%) rarely tran-
sitioned to disease. Given this heterogeneity, we used the avail-
able longitudinal samples to develop a kinetic understanding of 
how IgG ACPA V- domain glycosylation evolves in individuals who 
ultimately develop IA. Although the data are limited by the small 
number of those who transitioned to disease, it is clear that there 
is more than one trajectory and time course for disease devel-
opment, with some individuals demonstrating a rapid increase 
in glycosylation and others showing high levels for an extended 
period of time. These observations suggest that the acquisition 
of N- glycans in the ACPA V domain is a process that requires 
repeated T cell–dependent B cell hypermutation events, poten-
tially as a result of multiple hits that occur with varying kinetics. 
Ultimately, these may lead to the persistence, if not the patho-
genicity, of the ACPA response.
Our study is limited by the relatively small number of samples 
with longitudinal follow- up. Also, the number of samples with low- 
level ACPA that did not pass quality control may have introduced 
bias. However, except for ACPA levels, the patients who could 
be included in the analysis had similar baseline characteristics 
compared to those who had to be excluded because of technical 
limitations (Table 1). Furthermore, in samples that passed our strict 
controls, estimates of the predictive value of IgG ACPA V- domain 
glycosylation were substantial and hold promise for clinical appli-
cation. Nonetheless, additional studies are necessary to validate 
and extend these findings.
Finally, our study was conducted exclusively in an Indige-
nous North American population. Seropositive RA in this popu-
lation was associated with HLA–DRB1 SE–encoding alleles, as it 
is in most other populations worldwide. The primary SE allele in 
the Indigenous North American population is HLA–DRB1*14:02, 
which is prevalent in the background population and almost 
unique to Indigenous North Americans. In contrast to other 
RA- predisposing SE alleles such as HLA–DRB1*04:01, which 
is seen primarily in white populations, HLA–DRB1*14:02 can 
accommodate both citrulline and arginine peptides with compa-
rable affinity, but the orientation of citrulline- containing peptides 
is upright and directly interfaces with the T cell receptor (27,28). 
It is unclear whether these differences in peptide presentation to 
T cells impact their capacity to provide help for ACPA- expressing 
B cells. However, the observation that ACPA V- domain glyco-
sylation patterns are comparable in Indigenous North American 
and Dutch RA patients suggests that, irrespective of how T cell 
autoimmunity develops, the T cell–dependent SHM of ACPA B 
cells is a final common mechanism in the evolution of the ACPA 
response. Notably, tetanus toxoid–specific IgG did not show 
enhanced V- domain glycosylation in the Indigenous North Amer-
ican RA patients, in accordance with our previous  observations 
Figure 4. Development of RA in ACPA- positive FDRs, based on 
degree of IgG ACPA V- domain glycosylation at the first instance 
of sampling. IgG ACPA V- domain glycosylation levels below and 
above the 58.5% median are shown. HR = hazard ratio; 95% CI = 
95% confidence interval (see Figure 1 for other definitions).  Color 
figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40920/abstract.
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in Dutch RA patients and with the absence of additional 
N- glycosylation sites in B cell receptors of tetanus toxoid–spe-
cific B cells (13,14).
In summary, we have shown that IgG ACPA V- domain gly-
cosylation is a strong predictive biomarker for the development 
of ACPA- positive RA. Our findings have important implications 
for assessing the risk of future RA development in unaffected 
ACPA- positive individuals and, in turn, for stratifying these indi-
viduals for intervention studies. The results also provide mech-
anistic information regarding the evolution of preclinical RA 
autoimmunity. Future studies in this and other populations will be 
needed to determine the ultimate clinical utility of these findings.
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Clinical Image: Hypertrophic osteoarthropathy in cystic fibrosis
The patient, a 19- year- old man with cystic fibrosis (CF), presented with pain and swelling of both wrists in association with an infective 
respiratory exacerbation. His CF- related complications included clubbing, multilobar bronchiectasis, chronic infection with Pseudomonas 
aeruginosa, exocrine pancreatic insufficiency, CF- related diabetes mellitus, and low body mass. Examination revealed bilateral wrist swell-
ing and tenderness. Radiography of the hands and wrists demonstrated multi–layered periosteal reactions in the distal ulna and radius 
bilaterally (arrows), consistent with a diagnosis of hypertrophic osteoarthropathy (HOA) (1). While most commonly linked with non–small 
cell lung cancer, secondary HOA may occur with a range of pulmonary and extrapulmonary pathologies, including CF (2). The pathophys-
iologic mechanisms remain unclear. In our patient, treatment with intravenous antibiotics and oral corticosteroids was associated with 
significant improvement in both respiratory and joint symptoms.
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